Search

everythinglearnresearchcommunity

for

Search:↓

The user has been using oral minoxidil, dutasteride, and RU58841 but continues to experience hair loss. They seek advice on why the treatments aren't working and if others have had similar experiences.

A 57-year-old man with male pattern hair loss and insulin resistance experienced hair regrowth and weight loss after using tirzepatide, without other hair treatments. Dysregulated glucose metabolism is linked to hair loss, with tirzepatide potentially improving hair density by normalizing insulin resistance.

A new therapy aimed at destroying DHT receptors in the scalp is still in early trials and may take at least 5 years to become available. A sugar-like solution similar to Minoxidil is also in early testing stages and not yet commercialized.

RU58841, an anti-androgenic compound, showed early promise for treating alopecia but faced challenges after its patent in 1997. Despite advancing to Phase II trials, safety concerns and financial struggles led Aventis to abandon its development. Proskelia, which later merged into ProStrakan, couldn't prioritize the drug, leading to its eventual stagnation and failure to reach the market.

The conversation discusses the potential of using topical estrogen treatments for hair loss without systemic absorption, highlighting challenges and possible solutions like using estriol. It also mentions other treatments like topical finasteride, microneedling, and scalp massage, while noting the limitations and side effects of current options.

Reducing DHT in the scalp is ideal for hair retention, with topical finasteride and dutasteride being common treatments. Some users report side effects like reduced libido, while others experiment with higher doses for regrowth.

Hydrocortisone is not recommended for long-term use on the scalp due to potential side effects like thinning and steroid-related issues. Alternatives like foam minoxidil or oral minoxidil are suggested, though foam may be less effective.

A user is making their own dutasteride solution using MCT oil but is concerned about its effectiveness and bioavailability. They are considering using propylene glycol or adding ethanol for better results, while others suggest the current dosage might be excessive.

A 38-year-old woman has been using oral Dutasteride for a year without improvement and is now adding a topical solution containing Minoxidil, Dutasteride, Tretinoin, Ketoconazole, and Hydrocortisone. She is seeking advice on whether switching from oral to topical Dutasteride could prevent hair shedding.

Progesterone, hydrocortisone butyrate, and estrone base are discussed as treatments for hair loss. Topical progesterone and dutasteride are suggested to potentially reverse androgenic alopecia.

The user switched from oral minoxidil to topical minoxidil and added JXL-069/PP405-3HP, along with topical dutasteride, melatonin, and tretinoin. They also use low-level laser therapy (LLLT) but doubt its effectiveness.

User experienced scalp irritation from Kirkland 5% liquid minoxidil, likely due to propylene glycol. They are seeking non-PG liquid alternatives that are affordable.

The conversation discusses hair loss treatments like topical finasteride with minoxidil, oral dutasteride, and essential oils. Oral treatments like dutasteride and finasteride are seen as more effective, though some prefer topicals to avoid side effects.

The discussion revolves around the need for future oral DHT blockers for hair loss treatment that don't have the side effects of current options like Finasteride and Dutasteride. One user suggests that the future of hair loss treatment will likely be topical anti-androgens, as they can target hair follicles without affecting the entire system.

The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.

Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

A user is experiencing facial bloating from low-dose topical finasteride due to high estradiol levels and is seeking advice on using DIM to manage this issue, including dosage and brand recommendations.

Discussion on hair loss treatments, focusing on pp405, with skepticism about its effectiveness and concerns about its association with the cosmetic industry. Users also mention treatments like Minoxidil and Finasteride.

Hair loss, Minoxidil, finasteride, and RU58841 as potential treatments for it.

The conversation discusses hair loss linked to BDNF-increasing nootropics like Semax and Lions Mane. Suggested topical treatments include capsaicin, beta-glucan, and ginseng to counteract TGF-B activation.

Lichen Planopilaris (LPP), a form of permanent hair loss, which can be mistaken for seborrheic dermatitis and is characterized by scalp itching, burning, redness, and dandruff. Treatment options discussed include steroidal creams, finasteride, minoxidil, and RU58841.

The conversation is a humorous take on someone's reaction after their first dose of finasteride for hair loss. Specific treatments mentioned include scalp massage and a protocol of manifestation twice daily.

New product Tomorrowlabs HSF targets hair loss through HIF pathway indirectly by removing scalp iron. Minoxidil and Stemoxydine also relate to HIF pathway.

Clascoterone 5% solution is discussed as a potential new treatment for hair loss, offering an alternative for those who can't use finasteride or need additional options beyond minoxidil. Concerns about cost, effectiveness, and safety compared to existing treatments like RU58841 and finasteride are highlighted.

Concerns about the potential systemic effects and safety of PP405 for hair loss, with discussions on its comparison to existing treatments like finasteride and minoxidil. Users express skepticism about untested research chemicals and emphasize the importance of clinical trials to ensure safety and efficacy.

The user is anxious about potential side effects of finasteride, particularly PFS, and is considering reinstating it for hair loss treatment. They experienced anxiety-induced side effects previously and are seeking advice on overcoming their fear of restarting finasteride.

Maneup GHK-Cu peptide was used for hair loss, resulting in some hair growth in the receded hairline, but the new hairs were dry and split easily. Users discussed their experiences with this treatment.

The user is considering adding an anti-androgen, RU58841, to their current hair loss treatment routine due to receding hair. They are also contemplating waiting for Breezula or Pyrilutamide to become more affordable.

The conversation is about hair regrowth using topical finasteride, minoxidil, and keto spray, along with oral Saw Palmetto, Lustriva complex, collagen, and microneedling. Users discuss their experiences with these treatments, noting improvements in hair density and color, with some experiencing mild side effects.